Literature DB >> 9794839

Clinical applications of TNF-alpha in cancer.

F J Lejeune1, C Rüegg, D Liénard.   

Abstract

High-dose TNF-alpha plus chemotherapy, with or without IFN-gamma, can be safely administered regionally through isolated limb perfusion. This procedure produced between 70% and 80% complete remission in cases of in transit melanoma metastases and between 25% and 36% complete remission in cases of inextirpable soft-tissue sarcomas. Dual targeting is involved; TNF-alpha and IFN-gamma induce apoptosis of angiogenic endothelium, while melphalan induces apoptosis of tumour cells.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9794839     DOI： 10.1016/s0952-7915(98)80226-4

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  34 in total

1.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  FXR1 is elevated in colorectal cancer and acts as an oncogene.

Authors:  Xin Jin; Bo Zhai; Taishi Fang; Xiaohui Guo; Lishan Xu
Journal:  Tumour Biol       Date:  2015-09-24

3.  Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.

Authors:  Dennis Kobelt; Jutta Aumann; Manuel Schmidt; Burghardt Wittig; Iduna Fichtner; Diana Behrens; Margit Lemm; Greta Freundt; Peter M Schlag; Wolfgang Walther
Journal:  Mol Oncol       Date:  2014-01-18       Impact factor: 6.603

4.  Knockdown of miR-182 promotes apoptosis via regulating RIP1 deubiquitination in TNF-α-treated triple-negative breast cancer cells.

Authors:  Like Wo; Dezhao Lu; Xidong Gu
Journal:  Tumour Biol       Date:  2016-07-30

Review 5.  Cellular immunotherapy: antigen recognition is just the beginning.

Authors:  Daniel S Chen; Mark M Davis
Journal:  Springer Semin Immunopathol       Date:  2005-04-16

6.  Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis.

Authors:  Qianyi Gong; Changfeng Song; Xiaotong Wang; Renjie Wang; Guoxiang Cai; Xin Liang; Jianwen Liu
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-10

7.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Authors:  D Lecis; C Drago; L Manzoni; P Seneci; C Scolastico; E Mastrangelo; M Bolognesi; A Anichini; H Kashkar; H Walczak; D Delia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

8.  Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway.

Authors:  Chenghai Li; Zhengfeng Yang; Chunyan Zhai; Wenwei Qiu; Dali Li; Zhengfang Yi; Lei Wang; Jie Tang; Min Qian; Jian Luo; Mingyao Liu
Journal:  Mol Cancer       Date:  2010-04-06       Impact factor: 27.401

9.  Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.

Authors:  Filip Van Hauwermeiren; Marietta Armaka; Niki Karagianni; Ksanthi Kranidioti; Roosmarijn E Vandenbroucke; Sonja Loges; Maarten Van Roy; Jan Staelens; Leen Puimège; Ajay Palagani; Wim Vanden Berghe; Panayiotis Victoratos; Peter Carmeliet; Claude Libert; George Kollias
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

10.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.